168 related articles for article (PubMed ID: 21094281)
21. Performance comparison of an in-house integrase genotyping assay versus the ViroSeq™ Integra48, and study of HIV-1 integrase polymorphisms in Hong Kong.
To SW; Chen JH; Wong KH; Chan KC; Ng HM; Wu H; Lam JT; Yam WC
J Clin Virol; 2013 Sep; 58(1):299-302. PubMed ID: 23886504
[TBL] [Abstract][Full Text] [Related]
22. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Nguyen HL; Ruxrungtham K; Delaugerre C
Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
[TBL] [Abstract][Full Text] [Related]
23. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
24. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.
Van Laethem K; Schrooten Y; Covens K; Dekeersmaeker N; De Munter P; Van Wijngaerden E; Van Ranst M; Vandamme AM
J Virol Methods; 2008 Nov; 153(2):176-81. PubMed ID: 18706932
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
[TBL] [Abstract][Full Text] [Related]
27. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
Saeng-aroon S; Tsuchiya N; Auwanit W; Ayuthaya PI; Pathipvanich P; Sawanpanyalert P; Rojanawiwat A; Kannagi M; Ariyoshi K; Sugiura W
Antiviral Res; 2010 Jul; 87(1):22-9. PubMed ID: 20382184
[TBL] [Abstract][Full Text] [Related]
28. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
[TBL] [Abstract][Full Text] [Related]
30. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
31. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
[TBL] [Abstract][Full Text] [Related]
32. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.
Dimonte S; Babakir-Mina M; Aquaro S; Perno CF
Infection; 2013 Dec; 41(6):1097-102. PubMed ID: 23620062
[TBL] [Abstract][Full Text] [Related]
33. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
34. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
[TBL] [Abstract][Full Text] [Related]
36. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
37. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
Visco-Comandini U; Balotta C
Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
[TBL] [Abstract][Full Text] [Related]
38. [Study on the evolutionary pressure on the env gene of the human immunodeficiency virus type 1 CRF01-AE strains circulating in China].
Liang H; Xing H; Wei M; Chen Z; Guan Q; Huang HL; Quan Y; Chen JP; Hong KX; Shi LY; Shao YM
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):966-70. PubMed ID: 14687493
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong.
Yam WC; Chen JH; Wong KH; Chan K; Cheng VC; Lam HY; Lee SS; Zheng BJ; Yuen KY
J Clin Virol; 2006 Apr; 35(4):454-7. PubMed ID: 16386461
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
